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ABSTRACT
Background. Although breast cancer during pregnancy
(BCDP) is rare (occurring with only 0.4% of all BC diagnoses
in female patients aged 16–49 years), management decisions
are challenging to both the patient and the multidisciplinary
team.
Materials and Methods. Experts in breast cancer at the Uni-
versity of North Carolina conducted a targeted literature
search regarding the multidisciplinary treatment approaches
to BCDP: medical, surgical, and radiation oncology. Supportive
care, including antiemetic agents, and imaging approaches
were also reviewed.
Results. Review of the literature revealed key points in the
management of BCDP. Surgical management is similar to that in
nonpregnant patients; pregnant patients may safely undergo
breast-conserving surgery. Recommendations should be tai-
lored to the individual according to the clinical stage, tumor
biology, genetic status, gestational age, and personal
preferences. Anthracycline-based chemotherapy can be safely
initiated only in the second and third trimesters. The rate of
congenital abnormalities in children exposed to chemotherapy
is similar to the national average (approximately 3%). Dosing of
chemotherapy should be similar to that in the nonpregnant
patient (i.e., actual body surface area). Antihuman epidermal
growth factor receptor 2 therapy, radiation, and endocrine
treatment are contraindicated in pregnancy and lactation. Care
should include partnership with obstetricians. The literature
regarding prognosis of BCDP is mixed.
Conclusion. To maximize benefit and minimize risk to the
mother and fetus, an informed discussion with the patient and
her medical team should result in an individualized treatment
plan, taking into account the timing of the pregnancy and the
stage and subtype of the breast cancer. Because BCDP is rare, it
is essential to collect patient data in international registries.The
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Implications for Practice: Breast cancer during pregnancy is a major ethical and professional challenge for both the patient and the
multidisciplinary treatment team. Although the oncologic care is based on that of the non-pregnant breast cancer patient, there are
many challenges from regarding the medical, surgical and radiation oncology and obstetrical aspects of care that need to be
considered to deliver the safest and best treatment plan to both the mother and developing fetus.
INTRODUCTION
While breast cancer diagnosis during pregnancy (BCDP) is rel-
atively uncommon, accounting for only 0.4% of all breast
cancer diagnoses ages 16–49 years [1], it represents a sub-
stantial challenge to the patient and the multidisciplinary
team making management decisions. Despite a desire to
treat the pregnant patient with breast cancer as effectively
as the nonpregnant patient with breast cancer, the selection
and delivery of standard therapies must be modified to
ensure safety to both the mother and the fetus. Pregnancy-
associated breast cancer (PABC) has been defined in various
ways throughout the literature, including but not limited to
breast cancer diagnosed during a pregnancy, during lactation,
or up to 1 year (or more) after delivery. For the purposes of
this review, we are most focused on the care of the pregnant
patient with breast cancer (i.e., BCDP). However, we review
literature that refers to the term PABC, which may also
include patients diagnosed during lactation or soon after
delivery of a child. The overarching goal of this comprehen-
sive review is to summarize the oncologic approach of each
subspecialty involved in the care of the pregnant patient
with breast cancer, including medical, surgical, and radiation
oncology perspectives. In addition, it is imperative to involve
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maternal-fetal medicine early and throughout the care of the
pregnant patient with breast cancer in partnership with the
oncologic team. Herein, we provide evidence-based, practical
guidance to the optimal approach and treatment of patients
diagnosed with breast cancer during pregnancy.
MATERIALS AND METHODS
A targeted literature search in PubMed regarding BCDP (includ-
ing the terms “pregnancy,” “breast cancer,” and “pregnancy-
associated breast cancer,” as well as “breast cancer during
pregnancy,” along with drug names [i.e., “trastuzumab” and
“paclitaxel”] or other terms by topic [e.g., “survival outcomes”])
was performed by an expert in each respective discipline within
our multidisciplinary team at the University of North Carolina
at Chapel Hill: medical oncology, radiation oncology, surgical
oncology, and pharmacology. The targeted literature search
included epidemiology, diagnosis, treatment approach, and
outcomes of mother and fetus. The type of evidence (retro-
spective/prospective) is noted throughout the article and refer-
enced appropriately.
INCIDENCE AND EPIDEMIOLOGY
Compared with other malignancies, breast cancer is one of the
most common cancer diagnoses during pregnancy [2], with an
incidence of approximately 15 to 35 per 100,000 deliveries [3].
The incidence of cancer during pregnancy or lactation is
increasing [1, 2]. This observation is partially due to increasing
age at childbearing across the general population. The mean
age of mothers has increased since 2000, especially age at first
birth, which increased from 24.9 years in 2000 to 26.3 years in
2014 [4].
Investigators have evaluated the differential biology of
PABC, including the incidence of breast cancer subtypes. Genin
et al. conducted a retrospective study of 276 young women
younger than age 43 years diagnosed with breast cancer,
including 14.5% with PABC [5]. Those with PABC were signifi-
cantly younger than those with non-PABC (NPABC) and were
twice as likely to be diagnosed with a T3–T4 primary tumor.
Moreover, PABCs were twice as likely to be human epidermal
growth factor receptor 2 (HER2/neu) overexpressing and hor-
mone receptor negative as were NPABC. A second study sup-
ports the finding that PABC shares more aggressive features
compared with NPABC [6]. Among a total of 175 parous and
114 nonparous women diagnosed with breast cancer, those
within 2 years of last parity were more likely to have grade 3
tumors, positive lymph nodes, and triple-negative tumors.
HER2/neu overexpression and p53 status were similar between
groups.
Finally, and consistent with literature surrounding the biol-
ogy of young women’s breast tumors [7, 8], Murphy et al. eval-
uated the clinicopathologic features of PABC compared with
NPABC and how these features affect outcome. As per prior
reports, PABC was more likely than NPABC to be associated
with tumors that were estrogen and/or progesterone receptor
negative, larger in size, lymph node positive, and high grade.
While overall survival (OS) was not significantly different
between cases and controls (p5 .078), hormone receptor sta-
tus and nodal class were independent prognostic factors for
survival in both groups [9]. Our understanding of the biology of
BCDP continues to evolve and remains an area of active
research, with the goal of optimizing treatment options for
patients diagnosed with BCDP.
MATERNAL OUTCOMES
The literature on the prognosis of women diagnosed with PABC
has been mixed (Table 1). It is important to recognize the out-
comes of patients with BCDP compared with those who have
non-BCDP when making global treatment recommendations
for this group of patients.When adjusted for stage and subtype,
survival has been reported to be the same for BCDP and non-
BCDP, and routine termination of pregnancy after a diagnosis
of breast cancer does not improve survival [10]. However, for
women who present with advanced disease and poor progno-
sis early in the first trimester, termination may be considered to
avoid delay in treatment. Among patients who present with
low-burden metastatic disease past the first trimester, empha-
sis on single-agent medical therapy to control symptoms while
allowing term delivery should be the focus.
Among patients who present with low-burden meta-
static disease past the first trimester, emphasis on
single-agent medical therapy to control symptoms
while allowing term delivery should be the focus.
Several studies report similar maternal outcomes for PABC
and NPABC [11, 12]. For instance, in the prospective Cancer
and Pregnancy Study, Cardonick et al. report on outcomes by
stage for 130 women diagnosed with BCDP [10]. Evaluation of
survival by stage for a primary diagnosis during pregnancy was
similar to that in nonpregnant women matched for stage
(mean follow-up, 3.146 2.5 years) and was as follows: stage I,
100%; stage II, 86%; stage III, 86%; and stage IV, 0%.
Conversely, additional studies report worse survival for
women diagnosed with PABC versus NPABC. Results from the
California Cancer Registry (1991–1999) compared outcomes in
797 PABC cases (179 with BCDP) with outcomes in 4,177
NPABC controls. Rates of death were higher among those diag-
nosed with PABC than in NPABC cases (39.2% vs. 33.4%;
p5 .002), a result that held true in multivariable analysis [13].
Ali et al. reported on 40 women with PABC (17 with BCDP) and
40 with NPBAC treated between 1990 and 2005 [14]. Median
OS and disease-free survival (DFS) were significantly worse for
patients with PABC than for those with NPABC (4.9 and 2.7
years vs. 6 and 5.1 years, respectively). More recently, Azim
et al. conducted a meta-analysis of 30 studies that included
3,628 PABC cases and 37,100 NPABC controls [15]. The included
studies were control-matched, population-based, and hospital-
based studies that evaluated outcomes for PABC (diagnosis dur-
ing pregnancy and up to 2-years postpartum). Results indicated
that PABC patients were at higher risk for death (hazard ratio
[HR], 1.44; 95% confidence interval [CI], 1.27–1.63) and relapse
(DFS; HR, 1.6; 95% CI, 1.19–2.16) compared with NPABC
patients. Interestingly, there was a stronger trend toward worse
outcomes among patients diagnosed within 1 year postpartum
(HR, 1.84) compared with those diagnosed during pregnancy
(HR, 1.29). Collectively, however, in evaluating these data, it is
important to consider several points. Many of these studies
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include older series, during which delays in care and substan-
dard chemotherapy were recommended for patients with
BCDP. In addition, the population of patients studied ranged
from those diagnosed with BCDP, breast cancer during lacta-
tion, or breast cancer after delivery. Thus, on the basis of the
heterogeneity of the patient populations and treatments pre-
scribed, these results should be interpreted with caution.
CLINICAL PRESENTATION
Not surprisingly, most PABC is diagnosed as a self-palpated
breast mass. Most women diagnosed with BCDP are younger
than age 40 years and are not undergoing routine screening
mammography. Even for those age 40 years or older, screening
mammography during pregnancy is generally not recom-
mended because of the significantly reduced sensitivity of
mammography in this setting; hormone changes during preg-
nancy and lactation yield diffusely marked increases in breast
density. Heterogeneous breast density (50% to 75% density)
may obscure small masses, while extremely dense breasts
(>75% density) outright reduce mammographic sensitivity.
During pregnancy, there is a proliferation of glandular tissue
and differentiation of secretory units in preparation for lacta-
tion. These physiologic processes result in tenderness and an
increase in breast volume and density. Such changes compli-
cate the clinical breast exam and can delay identification of sus-
picious masses, resulting in more locally advanced disease at
the time of diagnosis. Any breast or axillary mass that persists
for longer than 2 weeks should be evaluated via diagnostic
imaging and, if indicated, by biopsy. Eighty percent of breast
masses identified during pregnancy are benign. The differential
diagnosis of pregnancy-associated breast masses includes
fibroadenoma; fibrocystic changes; galactocele; lactating
adenoma; lipoma; abscess; breast cancer; and, more rarely, sar-
coma, leukemia, and lymphoma [16].
IMAGING AND STAGING CONSIDERATIONS
Ultrasonography is the first line imaging modality for evaluation
of a breast mass during pregnancy because it can differentiate
between solid and cystic lesions and lacks ionizing radiation,
which may be associated with birth defects. In several studies,
ultrasonography had an extremely high sensitivity in the detec-
tion of BCDP and detected both benign and malignant lesions.
Robbins et al. reports a 100% sensitivity for ultrasonography
compared with 78%–100% for mammography [17]. Ultrasonog-
raphy is generally recommended for evaluating breast lesions
in women younger than age 30 years because of increased
breast density in this age group. However, in the dense breast
of pregnancy, ultrasonography is appropriate at all ages.
Ultrasonography-guided core biopsy can be performed for tis-
sue diagnosis.
Once malignancy has been identified or is strongly sus-
pected, mammography is also helpful to determine the extent
of disease, visualize suspicious microcalcifications, and evaluate
the contralateral breast, but with the limitations discussed in
the “Clinical Presentation” section. There is minimal risk to the
developing fetus with mammography because of modern
shielding techniques. Ionizing radiation exposure to the fetus is
less than 0.03 mGy, several orders of magnitude less than the
50,000-mGy threshold above which teratogenic effects are a
concern. Lead shielding reduces this risk an additional 50%,
suggesting that mammography with proper shielding presents
an exceptionally low risk to the developing fetus [18]. To put
these doses of ionizing radiation into perspective, a fetus is
exposed to an average of 1,000 mGy of background radiation
during normal development [19].
Table 1. Breast cancer-associated outcomes for women diagnosed with breast cancer during pregnancy
Study Sample size
Primary
objective
and FU Results
Cardonick et al.,
2010 [10]
n5 130 BCDP
FU, 3.14 (62.5) yra
OS Survival similar to that of nonpregnant, staged-
matched women (stage I, 100%; stage II, 86%;
stage III, 86%; and stage IV, 0%)
Rodriguez et al.,
2008 [13]
n5 797 PABC
(of these, n5179 BCDP)
n5 4,177 NPABC
OS Higher death rates for PABC (39.2%) vs. NPABC
(33.4%); p5 .002
Ali et al., 2012 [14] n5 40 PABC
(of these, n5 17 BCDP)
n5 40 NPABC
Median FU, 100/103 monthsa
OS
DFS
Survival worse for PABC (4.9 yr) vs. NPABC (6 yr),
p5 .002
DFS worse for PABC (2.7 yr) vs NPABC (5.1 yr),
p5 .01
Azim et al., 2012
[15]
n5 3,628 PABC
n5 37,100 NPABC
Very mixed cohorts: includes up to
2 yr after pregnancy
Meta-analysis
OS
DFS
Survival worse for PABC vs. NPABC (HR, 1.44)
DFS worse for PABC vs. NPABC (HR, 1.6)
Litton et al.,
2013 [12]
n5 75 BCDP
n5 150 NPABC
FU, 4.2 yr
OS
DFS
Survival similar to/better than that in
nonpregnant, staged and age-matched women
5-year OS: BCDP, 77%; NBCDP, 71% (p5 .0461)
DFS at 5 yr: BCDP, 72%; NBCDP, 57% (p5 .0115)
Amant et al.,
2013 [11]
n5 311 BCDP
n5 865 NBCDP
FU, 61 months
OS
DFS
Survival similar to that in nonpregnant patient
HR for OS, 1.34 (p5 .14)
HR for DFS, 1.19 (p5 .51)
Abbreviations: BCDP, breast cancer during pregnancy; DFS, disease-free survival; FU, follow-up; HR, hazard ratio; NBCDP, nonbreast cancer during
pregnancy; NPABC, non-pregnancy-associated breast cancer; OS, overall survival; PABC, pregnancy-associated breast cancer.
aFollow-up is mean/median as reported in the original paper.
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Magnetic resonance imaging (MRI) with contrast is not rec-
ommended during pregnancy. Gadolinium-based contrast has
been shown to cross the blood-placental barrier, and although
prospective clinical data are lacking, this agent is considered a
potential teratogen [20]. In breastfeeding women in the post-
partum period, MRI with contrast may safely be performed;
however, the images may be difficult to interpret given
increased background enhancement from hypervascularity and
lactational changes. There is evidence that negligible doses of
gadolinium-based contrast agents are excreted into breast milk,
but the risk for potential complications, including direct toxicity
or allergic reactions, is low and has not been reported in the lit-
erature. The American College of Radiology endorses the safety
of breastfeeding after MRI after potential risks have been dis-
cussed. If the mother remains concerned, it is recommended
she refrain from breastfeeding for 12–24 hours after adminis-
tration of gadolinium [21].
For advanced cancers, systemic staging studies are indi-
cated. The approach to the pregnant versus nonpregnant
patient, however, varies because of the risks of radiation and/
or contrast agents to the developing fetus. In the nonpregnant
patient, staging studies generally include contrast-enhanced
computed tomography (CT) and bone scanning or positron
emission tomography/CT. In the pregnant patient, staging stud-
ies should be performed only if they will change the treatment
recommendations. If they are necessary, they should include
chest radiography with abdominal shielding, liver ultrasonogra-
phy, and/or noncontrast skeletal MRI. Radionucleotide bone
scanning with hydration and an indwelling catheter may be
used when MRI is not available [22]. Contrast-enhanced CT is
generally not recommended during pregnancy.
SURGICAL CONSIDERATIONS
Surgical recommendations for women with BCDP are similar to
recommendations for women who are not pregnant. Recom-
mendations are based on the clinical stage, tumor biology,
genetic status, gestational age, and surgical desires of the
woman.
Gestational age at diagnosis is an important element of sur-
gical planning (Table 2). Because BCDP commonly presents
with locally advanced disease, systemic therapy has the poten-
tial advantage of treating both locoregional and distant disease.
Neoadjuvant chemotherapy has an added benefit of potentially
reducing the size of the cancer, making the patient a better can-
didate for breast conservation. Because BCDP patients are diag-
nosed at a young age, genetic testing is usually indicated.
Administration of neoadjuvant chemotherapy allows time for
results to be interpreted to guide surgical planning.
Historically, modified radical mastectomy was the standard
of care for women diagnosed with BCDP. The National Surgical
Adjuvant Breast and Bowel Project B-06 trial and other
randomized trials demonstrated that breast-conserving surgery
is as effective as mastectomy; however, there is a higher risk for
ipsilateral breast tumor recurrence in patients undergoing lum-
pectomy alone compared with those having lumpectomy fol-
lowed by adjuvant radiation [23]. As will be discussed in detail
later in this article, pregnant women cannot safely undergo
radiation. This previously precluded the use of breast conserva-
tion surgery in BCDP. Because many women will undergo
chemotherapy as part of their treatment plan, this regimen will
often extend until delivery, allowing for adjuvant radiation to
be safely given postpartum. This paradigm shift has made it
possible for BCDP patients to be candidates for breast conser-
vation surgery without compromising their cancer treatment.
Kuerer et al. reported on a series of 22 pregnant women with
stage I or II breast cancer from a prospective database; DFS and
OS did not differ when breast conservation surgery was com-
pared with modified radical mastectomy [24].
Historically, axillary lymph node dissection was considered
the standard of care during pregnancy because of concerns
about the safety of lymphoscintigraphy with 99m-Tc sulfur col-
loid. Several studies have documented the feasibility of lym-
phoscintigraphy during pregnancy and measured the uterine
dose of radiation from lymphoscintigraphy for sentinel lymph
node biopsy. Uterine radiation dose was calculated at 1.67 mGy,
much lower than the average background radiation of 8.2 mGy
per day and well below the 50,000 mGy threshold for fetal tera-
togenesis [25–28]. Sentinel lymph node biopsy should be con-
sidered standard of care for BCDP in the clinically negative
axilla. While the safety of 99m-Tc sulfur colloid has been estab-
lished, isosulfan blue dye should not be used because no ani-
mal or human studies have documented its safety. The U.S.
Food and Drug Administration (FDA) has classified isosulfan
blue dye as a category C drug.
Anesthetic considerations for surgery during pregnancy
include concern for the safety of two patients: the mother and
the fetus. Alterations in maternal anatomy and physiology
induced by pregnancy have clinical anesthetic implications and
present potential hazards for the mother and fetus undergoing
anesthesia. The fetus may be subjected to hazard by (a) the risk
for intraoperative hypoxemia or asphyxia caused by reduced
uterine blood flow, maternal hypotension, excessive maternal
mechanical ventilation or maternal hypoxia, and depression of
the fetal cardiovascular system or central nervous system from
placental passage of anesthetic agents; (b) exposure to terato-
genic drugs; and (c) the risk for preterm delivery as a
Table 2. Suggested surgical management of breast cancer
during pregnancy based on trimester at presentation
Trimester Surgical management
First 1. Chemotherapy not appropriate
2. Consider awaiting the second trimester to
initiate therapy depending on disease severity
and week of gestation
3. Consider surgery cautiously with RSI and FM
Second 1. Consider neoadjuvant chemotherapy to
downstage disease and allow for further
workup
2. Consider surgery (using RSI and FM) followed
by adjuvant chemotherapy
Third 1. Chemotherapy not appropriate unless it can
be halted approximately 3–4 wk before EDD;
can resume after delivery or proceed with
surgery after delivery
2. Consider surgery cautiously (using RSI, FM,
and proper positioning) followed by adjuvant
therapy after delivery
3. Consider awaiting or hastening delivery and
treating in the postpartum period depending
on disease severity and week of gestation/
fetal maturity
Abbreviations: EDD, estimated due date; FM, fetal monitoring; RSI,
rapid sequence induction.
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consequence of the surgical procedure or drugs administered
[29]. In most circumstances, the fetus is a passive recipient of
anesthesia administered to the mother, suffers no blood loss,
and undergoes passive changes rather than direct stress or
hemodynamic alterations caused by surgery.
Surgery can be safely performed at any time during preg-
nancy as long as certain issues are addressed. Anesthetic con-
siderations include the safety of both the mother and the fetus.
A population study has suggested that adverse fetal outcomes
after surgery may be due to the underlying maternal disease
rather than the direct effect of anesthesia [30]. Although there
is scant evidence of teratogenicity of commonly used anes-
thetic agents, surgery is not generally recommended until after
the first trimester, when organogenesis is complete, in order to
minimize potential risks to the developing fetus. Other consid-
erations include maternal physiologic changes, such as hyper-
coagulability, delayed gastric emptying, increased blood
volume and cardiac output, decreased functional residual
capacity of the lungs, and decreased serum cholinesterase
activity. Because of pregnancy-associated gastroesophageal
reflux, rapid sequence induction of anesthesia is preferred over
standard induction [16]. It is important to have a multidiscipli-
nary team involved, including the surgeon, anesthesiologist,
and maternal-fetal medicine specialist. The safest time to per-
form surgery during pregnancy is during the second trimester.
During the third trimester, the greatest risk to the fetus is pre-
mature labor and premature delivery, which can be initiated by
the stress of surgery. If surgery is necessary during the third tri-
mester, placing the patient in a 158 left lateral tilt position is
helpful to avoid aortocaval compression; intraoperative fetal
monitoring is imperative. Obstetric and neonatologic care
should be readily available, with access to a neonatal intensive
care unit.
As discussed earlier, neoadjuvant chemotherapy may
increase the feasibility of breast-conserving surgery and allow
time for the patient to make an informed surgical decision
based on genetic information. Initiating chemotherapy in the
second trimester and finishing in the third can allow for
planned delivery after fetal maturity while minimizing the risk
for chemotherapy-induced neutropenia at the time of parturi-
tion. Surgery may then be performed postpartum. Timing of
treatment initiation must be weighed against both the benefit
of delivery after fetal maturity and the risk for neutropenia.
Perioperative care of the pregnant patient should include
continued close fetal monitoring. Narcotic pain medications are
widely used during pregnancy. Dosage and duration should be
closely monitored to minimize infant dependency. Consultation
with anesthesia and obstetrics may be considered if extended
or high-dose analgesia regimens are required for adequate pain
control.
SYSTEMIC THERAPY
Chemotherapy
When chemotherapy is considered for women diagnosed with
BCDP, both pregnancy-related changes in maternal physiology
and stage of fetal development must be taken into account. For
instance, pregnancy is associated with dramatic changes in
blood volume, hepatic metabolism, and renal clearance, all of
which can affect adequate delivery of chemotherapy [31].
Although dose-adjusting chemotherapy is not recommended
during pregnancy, it is important to acknowledge that altered
metabolism and clearance may affect not only drug delivery
but also toxicity profiles. Perhaps one of the most important
considerations in the selection and timing of systemic therapy
is the effect of chemotherapy on fetal development. Following
implantation approximately 2 weeks after conception, organo-
genesis occurs over the course of the next 8 to 10 weeks, at
which time major malformations and fetal loss are most likely
to occur [32]. While studies of chemotherapy delivery during
the first trimester are few, fetal malformations, including neural
tube defects, cleft lip/palate, cardiac defects, and fetal loss,
have all been reported [32–34]. Thus, chemotherapy is contra-
indicated during the first trimester of pregnancy.
Although most studies evaluating the safety of chem-
otherapy beyond the first trimester have been retro-
spective, rates of fetal malformations have been low:
on average, 3%–5% across several studies, similar to
the rates in the population at large in the United
States and to those reported in a large German study
(6.9%).
During the second and third trimesters, the use of cytotoxic
chemotherapy is more widely accepted. Although most studies
evaluating the safety of chemotherapy beyond the first trimes-
ter have been retrospective, rates of fetal malformations have
been low: on average, 3%–5% across several studies [10,
35–38], similar to the rates in the population at large in the
United States [39] and to those reported in a large German
study (6.9%) [40]. A multicenter, case-control study of 129 chil-
dren who were exposed to maternal cancer with or without
treatment revealed that cognitive, cardiac, or general develop-
ment in early childhood was not impaired; however, prematur-
ity was correlated with worse cognitive outcome independent
of cancer treatment [41]. The fetal and maternal outcomes of
two notable studies—Hahn and colleagues (updated by Murthy
et al. [42]) and Loibl and colleagues (German report on the use
and safety of chemotherapy during pregnancy in a prospective
manner) [35, 42, 43]—are summarized in Table 3. Importantly,
the German study results illustrate that although more compli-
cations were reported for infants exposed to chemotherapy in
utero, complications were more common among infants born
prematurely, irrespective of exposure to chemotherapy [43].
Taking these data into account, we recommend that the
careful decision regarding timing of chemotherapy during preg-
nancy consider (a) standard clinicopathologic features (i.e.,
stage at diagnosis, lymph node status, grade, receptor status),
(b) gestational age at breast cancer diagnosis, and (c) the likeli-
hood of promoting a full-term delivery in an effort to maximize
both maternal and fetal outcomes. On the basis of the available
data, we would recommend initiation of systemic chemother-
apy after completion of the first trimester, in the absence of a
compelling contraindication.
With regard to choice of chemotherapy in the second and
third trimesters of pregnancy, the largest experience for both
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Table 3. Studies reporting on use and safety of chemotherapy during pregnancy
Study Drugs Pregnancy outcome Child outcomes
Prospective studies
MD Anderson
Hahn et al., 2006 [35]
Murthy et al.,
2014 [42]
n5 81 received
FAC
Gestational age at delivery: median (range),
37 (29–42) wk; no miscarriages, stillbirths, or
perinatal deaths
At median age of 7 yr; Down
syndrome (n5 1); congenital
anomalies (n5 2)
German Breast Group:
Loibl et al., 2012 [43]
n5 203 received
chemotherapy;
90% anthracycline,
8% CMF, 7% taxanes
n5 170 did not
receive
chemotherapy
Gestational age at delivery: median (range),
37 (23–42) wk); no statistical difference
between the chemotherapy and no-
chemotherapy group for spontaneous abor-
tion (0% vs. 2%; p5 .051) or stillbirths
(p5 .6); lower birth weight observed in new-
borns exposed to chemotherapy (n5 203)
compared with those not exposed to chemo-
therapy (n5 170; p5 .018)a; no statistical
difference between the chemotherapy and
no-chemotherapy group for premature deliv-
eries before week 37 of gestation; no differ-
ence in frequency of intrauterine growth
restriction or retardation (p5 .07), Apgar
scores (p5 not reported), or bleeding
(p5 .37) between fetuses exposed and not
exposed to chemotherapy
Malformations and newborn
complications were more common
in newborns born before
compared with after week 37 of
gestation (16% vs. 5%; p5 .0002)
and among those exposed to
chemotherapy in utero (15% vs.
4%; p5 .00045)
Case series/systematic reviews/meta-analysis
Taxanes
Zagouri et al., 2013
[46]
Systematic review
n5 50
Paclitaxel: 24%
Docetaxel: 30%
Taxane type not
specified: 42%
Both: 4%
Gestational age at delivery: median (range),
36 (30-40) wk; oligohydramnios and/or
anhydramnios (16.6%), mainly attributed to
trastuzumab (coadministrationin 75% of
cases with oligohydramnios and/or
anhydramnios)
27/30 (90%) of children were
completely healthy, with a median
follow-up of 16 months
Cardonick et al., 2012
[88]
Case series and
review of the
literatureb
n5 129
9% paclitaxel/
docetaxel
91%: nontaxane
chemotherapies
Gestational age at delivery: median (range),
36.9 (36.4–37.8) wk; birth weight, gestational
age at delivery, congenital anomalies, and
incidence of maternal and neonatal
neutropenia were not statistically different
between the two groups; congenital anomaly
occurred in one infant (6.25%)
Follow-up 46 (range, 18.3–96)
months; mean infant weight and
height percentiles were 49% and
40%, respectively
Mir et al., 2010 [48]
Systematic reviewc
n5 40
Paclitaxel: 53%
Docetaxel: 40%
Both: 7%
Gestational age at delivery: median (range),
36 (30–38) wk for paclitaxel, 35 (32–40) wk
for docetaxel; no spontaneous abortions or
intrauterine deaths; various malformations
(n5 1, diagnosed before docetaxel was
initiated); pyloric stenosis (n5 1, mother
had received multiagent regimens); anemia
(n5 1); intrauterine growth restriction
(n5 1); anhydramnios (n5 1, received
concurrent trastuzumab)
Follow-up: median (range), 15 (3–
132) months for paclitaxel; 18 (9–
36) months for docetaxel
No additional information
regarding late outcomes
Platinum
Zagouri et al., 2013
[47]
Systematic review
and meta-analysisd
n5 48
Cisplatin (n5 47)
Carboplatin (n5 1)
Gestational age at delivery: median (range),
33 (27–38) wk; 1/48 pregnancies resulted in
miscarriage; neonatal outcomes at birth:
completely healthy, 67.4%; mild elevation in
serum creatinine (n5 1); anemia (n5 1),
first-degree intraventricular hemorrhage
(n5 1); respiratory syndrome disorder
(n5 7); and respiratory syndrome disorder
combined with anemia (n5 1), with hypogly-
cemia (n5 1), with hypotension (n5 1), and
with supraventricular tachycardia (n5 1)
All children were healthy, with a
median follow-up of 12.5 months
K€ohler et al., 2015
[89]
Original report
transplacental
passage of platinumc
n5 21
Cisplatin (n5 20)
Carboplatin (n5 1)
Gestational age at delivery: mean (range),
NA (30–36) wk; platinum concentrations in
umbilical cord blood and amniotic fluid were
23%–65% and 11%–42% of the maternal
blood, respectively
After follow-up range of 7–88
months, all children were
without mental, hepatic, auditory,
renal, or hematopoietic
impairment
Abbreviations: CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; FAC, 5-fluorouracil, doxorubicin, cyclophosphamide; NA, not
available.
aAfter adjustment for gestational age.
bBreast and ovarian cancer.
cDifferent malignancies.
dCervical cancer.
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maternal and fetal outcomes has been with anthracycline-
containing regimens. Perhaps the largest study of a single regi-
men was of 5-fluourouracil, doxorubicin, and cyclophospha-
mide) [35]. Data with other regimens and other classes of
chemotherapy agents, including taxanes and platinum agents,
are more limited [44–47] (Table 3). Specifically, fetal outcomes,
although generally favorable after taxane and/or platinum ther-
apy, are based on a relatively small number of carefully selected
patients with relatively limited follow-up; thus, bias may be an
issue. We believe that taxanes and platinum agents should be
used cautiously to treat breast cancer during pregnancy, and
only if standard anthracycline-based therapy, as the favored
choice, is not feasible. Another concerning aspect of taxanes
during pregnancy is the higher activity of cytochrome P-3A4
during the third trimester; thus, taxane clearance is higher, with
possible limitations on expected efficacy [48]. This difficult deci-
sion relies on weighing the risks and benefits to the patient and
fetus.
In addition to type of chemotherapy, schedule of chemo-
therapy must also be considered. In the nonpregnant patient,
dose-dense chemotherapy has improved outcomes compared
with treatments every 3 weeks [49]. However, the use of
growth factors (i.e., granulocyte colony-stimulating factor) has
only recently been investigated in pregnancy [50, 51]. As noted
earlier, chemotherapy dosing in the pregnant patient should be
the same as in the nonpregnant patient and should be based
on actual body surface area calculation before every chemo-
therapy cycle [52].
Data regarding the safety of supportive drugs during preg-
nancy is relatively limited, and these medications should be
used during pregnancy only if the potential benefit justifies the
potential risk to the fetus (Table 4). The 5HT3 antagonists
ondansetron, palonosetron, and granisetron are classified as
pregnancy risk factor B. Few [53] or no reports have addressed
granisetron and palonosetron in human pregnancy, respec-
tively, but animal studies indicate that the risk of these agents
during pregnancy is low [54, 55]. Regarding ondansetron, sev-
eral studies support that this 5HT3 antagonist is not associated
with an increased risk for birth defects [56–58]. However, the
FDA has issued a warning regarding an increased risk for cardiac
arrhythmia (i.e., QT prolongation and torsades) in the general
population; therefore, maternal safety should be considered
[59–61]. No data in humans are available for neurokinin1 inhibi-
tors (i.e., aprepitant and fosaprepitant, pregnancy class B). Lim-
ited animal data suggest the risk during pregnancy may be low.
It is recommended to consider the dehydration and potential
toxicity risks and use accordingly [62].
Animal and human studies with corticosteroids are conflict-
ing but seem to suggest some increased risk for fetal risk, partic-
ularly in the first trimester. The benefits of corticosteroids are
generally thought to outweigh the risks [63]. Prednisolone and
hydrocortisone are preferred over dexamethasone because they
are highlymetabolized in the placenta and have limited penetra-
tion into the fetal compartment [64]. Antihistamines, H1 and H2
antagonists used to prevent allergic reactions with chemother-
apy, are generally considered safe for use during pregnancy.
Diphenhydramine, a first-generation H1 antagonist and
pregnancy risk factor B, has been associated with low fetal risk
in human and animal studies [65]. It is the preferred parenteral
H1 antagonist [66]. The H2 antagonists ranitidine, famotidine,
and cimetidine (pregnancy risk factor B) have low potential for
birth defects, as animal and human studies demonstrate [67].
Ranitidine is considered the drug of choice over famotidine and
cimetidine. Avoiding proton-pump inhibitors is recommended
because they might have a muscle-relaxant effect [52]. As dis-
cussed earlier, the use of granulocyte colony-stimulating factor
during pregnancy has recently been investigated, and data are
very limited. In a study of 176 pregnant women receiving
chemotherapy, 34 received filgrastim (Neupogen, Amgen,
Thousand Oaks, CA, http://www.amgen.com/) and/or peg-
filgrastim (Neulasta, Amgen). Study found no significant differ-
ences in the birth outcomes (including birth weight, preterm
birth, newborn mean white blood counts, and congenital mal-
formations) between groups [50].
Biologic Therapies
Because of adverse effects to the fetus, the use of trastuzumab,
a monoclonal antibody that targets HER2/neu, is contraindi-
cated during all trimesters of pregnancy. The FDA has catego-
rized trastuzumab as a Category D drug because of updated
safety information released in December 2010. Exposure to
trastuzumab during pregnancy has been associated with oligo-
hydramnios and oligohydramnios syndrome manifesting as pul-
monary hypoplasia, skeletal abnormalities, renal insufficiency,
and neonatal death. These findings have been noted I reports
and postmarketing experience with trastuzumab [68–70]. In
the unfortunate case of trastuzumab exposure during preg-
nancy, treatment should be discontinued and the fetus should
be closely monitored, with particular attention to amniotic fluid
volumes. Pertuzumab, a monoclonal antibody that blocks the
dimerization of HER2 and HER3, was approved by the FDA in
the neoadjuvant setting in 2013 based on higher pathologic
complete response rates for patients receiving pertuzumab in
addition to trastuzumab [71]. Pertuzumab has not been studied
in pregnant women and, similarly to trastuzumab, is contraindi-
cated during pregnancy [72]. In the setting of early-stage,
HER2-positive breast cancer diagnosed during pregnancy, tras-
tuzumab and/or pertuzumab can be administered after deliv-
ery and at completion of lactation if a patient elects to
breastfeed. There are no data regarding secretion of trastuzu-
mab (or pertuzumab) in human milk or effects on the breastfed
infant or milk production with trastuzumab in humans [73];
thus, it is not recommended.
Lapatinib, a small molecule tyrosine kinase inhibitor of both
the epithelial growth factor receptor (HER1) and HER2/neu, is
also indicated in the treatment of advanced trastuzumab-
refractory, HER2/neu-positive breast cancer [74]. Experience
with lapatinib during pregnancy is limited, and thus lapatinib can-
not be recommended during pregnancy. Collectively, anti-HER2
therapies are not recommended during pregnancy or breastfeed-
ing [75].
Endocrine Therapy
The mainstay of therapy for estrogen receptor- and/or pro-
gesterone receptor-overexpressing breast cancer is endo-
crine therapy in the form of tamoxifen or aromatase
inhibitor and ovarian suppression for premenopausal
women (http://www.nccn.org). The FDA has categorized
tamoxifen as a Category D drug; thus, it should be avoided
during pregnancy. Becoming pregnant while taking tamoxi-
fen or within 2 months after discontinuation has been
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associated with fetal malformations (Goldenhar syndrome,
manifested by oculoauriculovertebral dysplasia, as well as
ambiguous genitalia), vaginal bleeding, and miscarriage [34,
76–78]. Given these reports, initiation of tamoxifen is rec-
ommended after delivery. Moreover, tamoxifen significantly
delays postpartum milk production, and there are limited
safety data regarding excretion of tamoxifen in human milk.
Thus, we do not recommend tamoxifen during lactation
[79]. Of note, the decision to delay endocrine treatment in
order to allow lactation should be based on individual risk
and include a balanced discussion of risk versus benefit.
Radiation Safety Issues
Pregnancy is considered one of the few absolute contraindica-
tions to the use of radiotherapy (RT) because of the potential
teratogenic and even lethal effects on the developing fetus.
Most data regarding the effect of RT on pregnancy are based
on animal models, although evidence in humans was also
derived from the study of the atomic bombings of Hiroshima
and Nagasaki, Japan [80]. The effects of RT on the developing
fetus can be classified as lethal effects, malformations, and
growth disturbances without malformations [81]. The two
most important factors in discussing the effects of RT on the
fetus are the actual dose received and the occurrence of the
dose relative to the stage of pregnancy.
When one examines data from the atomic bombings in
Japan, the most common effects seen in children whose
mothers received incidental RT are microcephaly and mental
retardation [82–85]. Interestingly, RT-induced microcephaly
was seen in children who were irradiated from 0 to 15 weeks’
gestation, whereas mental retardation was not seen from 0 to
8 weeks [84, 85]. The highest incidence of RT-induced mental
retardation peaked at 8 to 15 weeks’ gestation, where the risk
was postulated to be 40% for every 1 Gy (unit of radiation)
received by the fetus; typical doses used for breast cancer are
on the order of 60 Gy. The incidence drops by nearly four-fold if
a fetus is irradiated from weeks 16 to 25.
Because RT is a known carcinogen, there is also concern for
induction of malignancy in fetuses that are exposed. Although
an issue of considerable debate, the exposure of a fetus in
utero is postulated to increase the fetus’s risk for cancer [86].
The malignancy with the most convincing link to RT is leukemia.
It is postulated that doses as low as 10 milli-Gy increase the
risk, with an absolute increase in developing a cancer second-
ary to RTof 6% per 1 Gy received.
RT’s acute effect on maternal lactation has not been stud-
ied; however, there is some evidence that women who have
received chest RT are capable of future lactation, although per-
haps not as well as their non-irradiated age-matched cohort
[87]. From a pragmatic standpoint, we recommend against
breastfeeding during RT treatment because the suckling effect
from the infant can augment skin toxicity secondary to the RT,
resulting in discomfort, skin breakdown, and possible infections
(i.e., mastitis).
Table 4. Safety information for selected supportive care agents administered during treatment for pregnancy-associated
breast cancer
Category Drug name
FDA
category Safety data/FDA cautions
G-CSF Filgrastim;
pegfilgrastim
C Filgrastim should only be used during pregnancy if the potential benefit
justifies the potential risk to the fetus. It is not known whether filgrastim is
excreted in human milk. In a study of 176 pregnant women receiving
chemotherapy, 34 received filgrastim (Neupogen) and/or pegfilgrastim
(Neulasta). In this study, there were no significant differences between the
birth outcomes (including birth weight, preterm birth, mean white blood
counts, and congenital malformations) between groups [50].
Antiemetics Ondansetron B While ondansetron is generally considered safe during pregnancy, the FDA
issued a warning about its risk to induce potentially fatal heart arrhythmia
(including torsade de pointes) in 2011
Compazine NA Prolonged jaundice, extrapyramidal signs, hyperreflexia, and hyporeflexia
have been reported in newborn infants whose mothers received
phenothiazines [90]
Promethazine C Specific studies to test the action of promethazine on parturition, lactation,
and development of the animal neonate were not done, but a general
preliminary study in rats indicated no effect on these parameters. Although
antihistamines have been found to produce fetal mortality in rodents, the
pharmacologic effects of antihistamine in the rodent do not parallel those
in humans.
Neurokinin 1
inhibitors
Aprepitant B There are insufficient data on use of aprepitant (Emend, Merck,
Whitehouse Station, NJ, http://www.merck.com) in pregnant women to
inform a drug-associated risk. In animal reproduction studies, no adverse
developmental effects were observed in rats or rabbits exposed during the
period of organogenesis to systemic drug levels (AUC) approximately 1.5
times the adult human exposure.
Corticosteroids Methylprednisolone;
dexamethasone
C Animal studies in which dexamethasone was given to pregnant mice, rats,
and rabbits have yielded an increased incidence of cleft palate in the
offspring. There are no adequate or well-controlled studies in pregnant
women. Infants born to mothers who have received corticosteroids during
pregnancy should be carefully observed for signs of hypoadrenalism [90].
Abbreviations: AUC, area under the receiver-operating characteristic curve; FDA, Food and Drug Administration; G-CSF, granulocyte colony-
stimulating factor; NA, not available.
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CONCLUSIONS AND RECOMMENDATIONS
BCDP is a major ethical and professional challenge for both the
patient and the multidisciplinary treatment team. While the
foundation of oncologic care is based on that of the NBCDP
patient, there are many unique issues from the medical, surgi-
cal, and radiation oncology perspectives that must be consid-
ered to ensure safety to both the mother and developing fetus.
Many of these key points and important contraindications are
summarized in Table 5. An informed discussion between the
patient and her medical team that generates an individualized
treatment plan, taking into account the timing of the pregnancy
and the stage and subtype of the breast cancer, is essential to
maximize benefit and minimize risk to the mother and fetus.
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